Omda AS, a leading provider of specialised software for healthcare and emergency
response, today announced the acquisition of Dermicus AB, a telemedicine
solutions company specialising in teledermatology and telewound care. Including
Dermicus in Omda's portfolio will further strengthen the groupŽs position in the
market for medical imaging solutions. 

Omda has entered into a binding agreement to acquire 100% of Dermicus AB.
Completion of the transaction is subject to FDI filing and approval, which are
expected to be obtained within 25 working days of signing. 

The Dermicus platform provides specialised mobile applications and workflows
designed for the remote diagnosis and management of skin conditions and chronic
wounds. It enables the secure capture and remote review of patient images by
specialists, streamlining the diagnostic process and enhancing accessibility to
specialist care. In NHS regions in the UK, Dermicus has reduced dermatology
waiting times from 26 days to under one day by enabling rapid assessments and
the prioritisation of high-risk individuals.

The solution integrates AI support for image quality control and Dermicus has
ongoing development and research projects with healthcare providers for AI
supported diagnostics.

The Dermicus platform is widely used by public and private healthcare providers,
with Sweden as its core market. Key customers include Region Stockholm and
Region Skåne. Outside Sweden, the company serves customers in Australia,
Austria, and the United Kingdom. Dermicus has 9 employees and is based in
Gothenburg and Stockholm, Sweden.

With the acquisition of Dermicus, Omda extends its product offering in the
medical imaging domain. Omda is a leading provider of imaging solutions in the
Nordics, offering secure, end-to-end systems for managing medical images. The
solutions are trusted by healthcare providers of all sizes, from small clinics
to extensive regional and national imaging networks.

Sverre Flatby, Chief Executive Officer of Omda, sees opportunities for further
growth by including Dermicus in Omda's portfolio: "Dermicus has proven to
connect hospitals, primary care and other professionals in the care value chain
facilitating efficient workflows and better outcomes for patients. The usability
of the mobile interface and the specialised workflows for all user groups
broadens the target group for solutions on this platform. The solution
complements our existing solutions in medical imaging and introduces a new way
to use AI which will enhance other products in the portfolio and ultimately
benefit our customers."

Daniel Eliasson, Dermicus CEO also emphasises the synergies and growth
opportunities: "Joining a large, international group like Omda will allow us to
expand our footprint both in current markets and internationally. Our solutions
are highly configurable and designed to integrate easily with the many systems
across the care ecosystem. We aim to add value quickly for new user groups that
already benefit from Omda's solutions and to explore how our experience with
mobile imaging and AI can have wider applications in other specialised
healthcare fields."

Acquisition details:
o	Signing took place on December 20, 2024.
o	Dermicus has budgeted sales for 2025 of 14 MSEK and positive EBITDAC
(management forecast).
o	The agreed transaction price is 19 MSEK and will be settled in two tranches